Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study-Reference-Cited by-同舟云学术

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Published:2018-02 Issue:2 Volume:19 Page:207-215
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lee Jung-Min,Nair Jayakumar,Zimmer Alexandra,Lipkowitz Stanley,Annunziata Christina M,Merino Maria J,Swisher Elizabeth M,Harrell Maria I,Trepel Jane B,Lee Min-Jung,Bagheri Mohammad H,Botesteanu Dana-Adriana,Steinberg Seth M,Minasian Lori,Ekwede Irene,Kohn Elise C

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Management strategies for recurrent platinum-resistant ovarian cancer;Naumann;Drugs,2011

3. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov,2015

4. Achieving precision death with cell-cycle inhibitors that target DNA replication and repair;Lin;Clin Cancer Res,2017

5. Checkpoint kinase 1 in DNA damage response and cell cycle regulation;Patil;Cell Mol Life Sci,2013

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and molecular features of platinum resistance in ovarian cancer;Critical Reviews in Oncology/Hematology;2024-09

2. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

3. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

4. Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer;Scientific Reports;2024-07-29

5. CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1;Cell Death & Disease;2024-06-19